LY-411575 (BioDeep_00000425852)

   


代谢物信息卡片


(S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide

化学式: C26H23F2N3O4 (479.1657)
中文名称: (aS)-N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[b,d]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟-alpha-羟基苯乙酰胺
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3N(C1=O)C)NC(=O)C(C4=CC(=CC(=C4)F)F)O
InChI: InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1

描述信息

D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators

同义名列表

5 个代谢物同义名

(S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide; LY-411575; (2S)-2-[[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-N-[(7S)-5-methyl-6-oxo-7H-benzo[d][1]benzazepin-7-yl]propanamide; LY 411575; LY411575



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Jianhai Chen, Wenxiang Cheng, Jian Li, Yan Wang, Jingqin Chen, Xin Shen, Ailing Su, Donghao Gan, Liqing Ke, Gang Liu, Jietao Lin, Liang Li, Xueling Bai, Peng Zhang. Notch-1 and Notch-3 Mediate Hypoxia-Induced Activation of Synovial Fibroblasts in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.). 2021 10; 73(10):1810-1819. doi: 10.1002/art.41748. [PMID: 33844448]
  • Jingjing Zhang, Gongqiang Yuan, Muchen Dong, Ting Zhang, Gao Hua, Qingjun Zhou, Weiyun Shi. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochemistry and cell biology. 2017 Mar; 147(3):367-375. doi: 10.1007/s00418-016-1484-x. [PMID: 27600720]
  • Rachelle S Doody, Rema Raman, Martin Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Feng He, Xiaoying Sun, Ronald G Thomas, Paul S Aisen, Eric Siemers, Gopalan Sethuraman, Richard Mohs. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. The New England journal of medicine. 2013 Jul; 369(4):341-50. doi: 10.1056/nejmoa1210951. [PMID: 23883379]
  • Mosun A Ayan-Oshodi, Brian A Willis, William F Annes, Stephen L Lowe, Stuart Friedrich, Amparo de la Peña, Wei Zhang, Thomas Brown, Stephen D Wise, Stephen D Hall. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. Drug metabolism and disposition: the biological fate of chemicals. 2012 Oct; 40(10):1945-52. doi: 10.1124/dmd.112.046060. [PMID: 22789530]
  • Brian A Willis, Wei Zhang, Mosun Ayan-Oshodi, Stephen L Lowe, William F Annes, Paul J Sirois, Stuart Friedrich, Amparo de la Peña. Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. Journal of clinical pharmacology. 2012 Jun; 52(6):904-13. doi: 10.1177/0091270011407195. [PMID: 21724950]
  • Ting Li, Yunhong Huang, Shiyi Jin, Liang Ye, Na Rong, Xiujuan Yang, Yu Ding, Ziqiang Cheng, Jinqiang Zhang, Zehong Wan, David C Harrison, Ishrut Hussain, Adrian Hall, Daniel Hong Seng Lee, Lit-Fui Lau, Yasuji Matsuoka. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. Journal of neurochemistry. 2012 Apr; 121(2):277-86. doi: 10.1111/j.1471-4159.2011.07560.x. [PMID: 22035227]
  • Yasong Lu, Liming Zhang, Charles E Nolan, Stacey L Becker, Kevin Atchison, Ashley E Robshaw, Leslie R Pustilnik, Sarah M Osgood, Emily H Miller, Antonia F Stepan, Chakrapani Subramanyam, Ivan Efremov, Andrew J Hallgren, David Riddell. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors. The Journal of pharmacology and experimental therapeutics. 2011 Dec; 339(3):922-34. doi: 10.1124/jpet.111.186791. [PMID: 21930801]
  • Ping Yi, Chad Hadden, Palaniappan Kulanthaivel, Nathan Calvert, William Annes, Thomas Brown, Robert J Barbuch, Archana Chaudhary, Mosun A Ayan-Oshodi, Barbara J Ring. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug metabolism and disposition: the biological fate of chemicals. 2010 Apr; 38(4):554-65. doi: 10.1124/dmd.109.030841. [PMID: 20075192]
  • Erik Portelius, Bianca Van Broeck, Ulf Andreasson, Mikael K Gustavsson, Marc Mercken, Henrik Zetterberg, Herman Borghys, Kaj Blennow. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. Journal of Alzheimer's disease : JAD. 2010; 21(3):1005-12. doi: 10.3233/jad-2010-100573. [PMID: 20634579]
  • David B Henley, Patrick C May, Robert A Dean, Eric R Siemers. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy. 2009 Jul; 10(10):1657-64. doi: 10.1517/14656560903044982. [PMID: 19527190]
  • Bruno P Imbimbo, Ilaria Peretto. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. Current opinion in investigational drugs (London, England : 2000). 2009 Jul; 10(7):721-30. doi: NULL. [PMID: 19579178]
  • Monica Garcia-Alloza, Meenakshi Subramanian, Diana Thyssen, Laura A Borrelli, Abdul Fauq, Pritam Das, Todd E Golde, Bradley T Hyman, Brian J Bacskai. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Molecular neurodegeneration. 2009 May; 4(?):19. doi: 10.1186/1750-1326-4-19. [PMID: 19419556]
  • Dorothee Abramowski, Karl-Heinz Wiederhold, Ulrich Furrer, Anne-Lise Jaton, Anton Neuenschwander, Marie-Josephine Runser, Simone Danner, Julia Reichwald, Domenico Ammaturo, Dieter Staab, Markus Stoeckli, Heinrich Rueeger, Ulf Neumann, Matthias Staufenbiel. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. The Journal of pharmacology and experimental therapeutics. 2008 Nov; 327(2):411-24. doi: 10.1124/jpet.108.140327. [PMID: 18687920]
  • Adam S Fleisher, Rema Raman, Eric R Siemers, Lida Becerra, Christopher M Clark, Robert A Dean, Martin R Farlow, James E Galvin, Elaine R Peskind, Joseph F Quinn, Abdullah Sherzai, B Brooke Sowell, Paul S Aisen, Leon J Thal. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives of neurology. 2008 Aug; 65(8):1031-8. doi: 10.1001/archneur.65.8.1031. [PMID: 18695053]
  • Eric R Siemers, Robert A Dean, Stuart Friedrich, Lisa Ferguson-Sells, Celedon Gonzales, Martin R Farlow, Patrick C May. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clinical neuropharmacology. 2007 Nov; 30(6):317-25. doi: 10.1097/wnf.0b013e31805b7660. [PMID: 18090456]
  • Lynn A Hyde, Nansie A McHugh, Joseph Chen, Qi Zhang, Denise Manfra, Amin A Nomeir, Hubert Josien, Thomas Bara, John W Clader, Lili Zhang, Eric M Parker, Guy A Higgins. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. The Journal of pharmacology and experimental therapeutics. 2006 Dec; 319(3):1133-43. doi: 10.1124/jpet.106.111716. [PMID: 16946102]
  • Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, Nikolay Pozdnyakov, Ping Du, Mary A Piotrowski, Tracy M Brown, Charles E Nolan, Karl E G Richter, James E Finley, Qing Fei, Charles F Ebbinghaus, Yuhpyng L Chen, Douglas K Spracklin, Barbara Tate, Kieran F Geoghegan, Lit-Fui Lau, David D Auperin, Joel B Schachter. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. The Journal of pharmacology and experimental therapeutics. 2006 Nov; 319(2):924-33. doi: 10.1124/jpet.106.110700. [PMID: 16920992]
  • E R Siemers, J F Quinn, J Kaye, M R Farlow, A Porsteinsson, P Tariot, P Zoulnouni, J E Galvin, D M Holtzman, D S Knopman, J Satterwhite, C Gonzales, R A Dean, P C May. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006 Feb; 66(4):602-4. doi: 10.1212/01.wnl.0000198762.41312.e1. [PMID: 16505324]
  • Eric Siemers, Michael Skinner, Robert A Dean, Celedon Gonzales, Julie Satterwhite, Martin Farlow, Daniel Ness, Patrick C May. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clinical neuropharmacology. 2005 May; 28(3):126-32. doi: 10.1097/01.wnf.0000167360.27670.29. [PMID: 15965311]
  • Thomas A Lanz, John D Hosley, Wade J Adams, Kalpana M Merchant. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). The Journal of pharmacology and experimental therapeutics. 2004 Apr; 309(1):49-55. doi: 10.1124/jpet.103.060715. [PMID: 14718585]